Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD
See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG
To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html
Study Counts
| Total_Studies |
1432 |
| interventional |
1295 |
| Observational |
132 |
| Registry |
5 |
Interventional Trials
Intervention Type
| Behavioral |
492 |
| Other |
213 |
| Drug|placebo |
125 |
| Dietary Supplement |
119 |
| Dietary Supplement|placebo |
79 |
| Drug |
70 |
| Behavioral|Other |
49 |
| Device |
19 |
| Dietary Supplement|Other |
16 |
| Other|placebo |
13 |
| Procedure |
13 |
| Device|placebo |
12 |
| Behavioral|Drug |
11 |
| Behavioral|Device |
10 |
| Behavioral|Dietary Supplement |
8 |
| Device|Other |
7 |
| Drug|Other|placebo |
6 |
| Behavioral|Drug|placebo |
5 |
| Behavioral|Dietary Supplement|Other |
3 |
| Behavioral|Dietary Supplement|placebo |
3 |
| Combination Product |
3 |
| Device|Drug |
3 |
| Diagnostic Test |
2 |
| Drug|Procedure |
2 |
| Behavioral|Device|Other |
1 |
| Behavioral|Dietary Supplement|Other|placebo |
1 |
| Biological|Other |
1 |
| Biological|placebo |
1 |
| Device|Dietary Supplement |
1 |
| Device|Drug|placebo |
1 |
| Dietary Supplement|Drug |
1 |
| Dietary Supplement|Other|placebo |
1 |
| Drug|Other |
1 |
| Drug|Other|placebo|Radiation |
1 |
| Genetic|Other |
1 |
| placebo |
1 |
Count of Studies by Intervention (normalized and mapped)
Interventions over Time
Weekly studies for each intervention
Studies by Country
| United States |
631 |
| NA |
106 |
| Canada |
58 |
| Germany |
46 |
| Spain |
38 |
| United Kingdom |
34 |
| Netherlands |
31 |
| Denmark |
27 |
| France |
27 |
| Norway |
24 |
| China |
22 |
| Iran, Islamic Republic of |
19 |
| Italy |
19 |
| Sweden |
19 |
| Brazil |
17 |
| Mexico |
14 |
| Korea, Republic of |
12 |
| Switzerland |
9 |
| Malaysia |
8 |
| Israel |
7 |
| Finland |
6 |
| Poland |
6 |
| Colombia |
5 |
| Greece |
5 |
| India |
5 |
| Portugal |
5 |
| Belgium |
4 |
| Hong Kong |
4 |
| Australia |
3 |
| Egypt |
3 |
| Taiwan |
3 |
| Thailand |
3 |
| Chile |
2 |
| Cuba |
2 |
| Germany|Italy |
2 |
| Ireland |
2 |
| Jordan |
2 |
| Lithuania |
2 |
| Qatar |
2 |
| Saudi Arabia |
2 |
| United States|Canada |
2 |
| United States|Puerto Rico |
2 |
| United States|United Kingdom |
2 |
| Australia|New Zealand |
1 |
| Austria |
1 |
| Bangladesh |
1 |
| Belgium|Denmark|Finland|Germany|Netherlands|Sweden|United Kingdom |
1 |
| Belgium|Singapore |
1 |
| Bolivia |
1 |
| Brunei Darussalam |
1 |
| Czechia|Denmark|Italy |
1 |
| Ecuador |
1 |
| Finland|Netherlands|Sweden |
1 |
| Finland|Sweden |
1 |
| Germany|Hungary|United Kingdom |
1 |
| Germany|Switzerland |
1 |
| Germany|United Kingdom |
1 |
| Greece|Hungary|Italy|Spain |
1 |
| Indonesia |
1 |
| Japan |
1 |
| Japan|Korea, Republic of |
1 |
| Lebanon |
1 |
| Netherlands|Sweden|United Kingdom |
1 |
| New Zealand |
1 |
| Nigeria |
1 |
| Romania |
1 |
| Romania|Spain|Sweden |
1 |
| Singapore |
1 |
| Tunisia |
1 |
| Turkey |
1 |
| Ukraine|United States|Denmark|Israel|Netherlands|Portugal|South Africa|Spain|Sweden|Switzerland |
1 |
| United States|Algeria|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Colombia|Croatia|Czechia|Denmark|Finland|France|Germany|Greece|Hungary|India|Ireland|Israel|Italy|Japan|Latvia|Malaysia|Mexico|Netherlands|Norway|Poland|Portugal|Puerto Rico|Romania|Russian Federation|Serbia|South Africa|Spain|Sweden|Taiwan|Thailand|Turkey|Ukraine|United Kingdom |
1 |
| United States|Algeria|Argentina|Canada|Germany|Greece|India|Japan|Puerto Rico|Russian Federation|South Africa|Spain|United Arab Emirates|United Kingdom |
1 |
| United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Denmark|Finland|Former Serbia and Montenegro|France|Germany|Hong Kong|Hungary|India|Ireland|Israel|Italy|Mexico|Netherlands|Norway|Poland|Russian Federation|Serbia|South Africa|Spain|Switzerland|Turkey|United Kingdom |
1 |
| United States|Argentina|Belgium|Bulgaria|Canada|Denmark|Finland|France|Germany|India|Japan|Mexico|Poland|Puerto Rico|Russian Federation|Taiwan|United Kingdom |
1 |
| United States|Argentina|Brazil|China|India|Japan|Mexico|Puerto Rico|Russian Federation|Taiwan |
1 |
| United States|Argentina|Colombia|Finland|Germany|Italy|Russian Federation|Spain|Sweden |
1 |
| United States|Australia |
1 |
| United States|Australia|Bahamas|Canada|Chile|Mexico|New Zealand|Poland |
1 |
| United States|Austria|Belgium|Croatia|Ireland|Mexico|Russian Federation|United Kingdom |
1 |
| United States|Austria|Canada|Czechia|Hungary|Slovakia|United Kingdom |
1 |
| United States|Belgium |
1 |
| United States|Brazil|United Kingdom |
1 |
| United States|Bulgaria|Canada|Czechia|Germany|Mexico|Russian Federation|Slovakia |
1 |
| United States|Canada|Czechia|Denmark|Hungary|Italy|Poland|United Kingdom |
1 |
| United States|Canada|Czechia|Denmark|Italy|Spain |
1 |
| United States|Canada|Denmark|Finland|Ireland|Japan|Poland|Serbia|South Africa|United Kingdom |
1 |
| United States|Canada|Denmark|Germany|Italy |
1 |
| United States|Canada|Germany|Israel|Italy|Mexico|Turkey |
1 |
| United States|Canada|Hungary|Italy|Spain |
1 |
| United States|Czechia|Denmark|Italy|Spain |
1 |
| United States|France|Germany|India|Israel|Italy|Puerto Rico|South Africa|Spain|Sweden|Taiwan|Turkey|United Kingdom |
1 |
| United States|Germany |
1 |
| United States|Israel |
1 |
| United States|Sweden |
1 |
| Vietnam |
1 |
Sites per Study
| 1 |
1103 |
| 2 |
87 |
| 3 |
21 |
| 4 |
15 |
| 5 |
6 |
| 6 |
6 |
| 7 |
1 |
| 8 |
3 |
| 9 |
4 |
| 10 |
3 |
| 11 |
1 |
| 12 |
2 |
| 13 |
3 |
| 15 |
2 |
| 16 |
4 |
| 17 |
2 |
| 18 |
2 |
| 19 |
1 |
| 23 |
1 |
| 25 |
1 |
| 27 |
1 |
| 29 |
1 |
| 30 |
1 |
| 32 |
1 |
| 34 |
3 |
| 36 |
4 |
| 38 |
1 |
| 40 |
1 |
| 44 |
1 |
| 53 |
1 |
| 54 |
1 |
| 55 |
1 |
| 72 |
1 |
| 83 |
1 |
| 119 |
1 |
| 125 |
1 |
| 131 |
1 |
| 150 |
1 |
| 161 |
1 |
| 226 |
1 |
| 499 |
1 |
| 806 |
1 |
Phase
| N/A |
964 |
| Phase 2 |
87 |
| Phase 1 |
85 |
| Phase 3 |
60 |
| Phase 4 |
54 |
| Phase 1/Phase 2 |
21 |
| Phase 2/Phase 3 |
16 |
| Early Phase 1 |
8 |
Number of Arms
| 1 |
142 |
| 2 |
757 |
| 3 |
209 |
| 4 |
93 |
| 5 |
17 |
| 6 |
13 |
| 7 |
5 |
| 8 |
5 |
| 12 |
2 |
| 13 |
1 |
| NA |
51 |
Number of Updates
| 1 |
198 |
| 2 |
234 |
| 3 |
182 |
| 4 |
175 |
| 5 |
119 |
| 6 |
92 |
| 7 |
66 |
| 8 |
48 |
| 9 |
27 |
| 10 |
35 |
| 11 |
28 |
| 12 |
20 |
| 13 |
8 |
| 14 |
4 |
| 15 |
7 |
| 16 |
9 |
| 17 |
3 |
| 18 |
5 |
| 19 |
4 |
| 20 |
5 |
| 21 |
1 |
| 22 |
1 |
| 23 |
1 |
| 25 |
1 |
| 26 |
1 |
| 27 |
1 |
| 31 |
3 |
| 32 |
1 |
| 33 |
1 |
| 39 |
1 |
| 40 |
2 |
| 41 |
1 |
| 48 |
1 |
| 51 |
1 |
| 57 |
1 |
| 60 |
1 |
| 80 |
1 |
| 86 |
1 |
| 89 |
1 |
| 104 |
1 |
| 125 |
1 |
| 131 |
1 |
| 133 |
1 |
Update History Change Type
| Study Status |
5858 |
1097 |
5.340018 |
| Contacts/Locations |
2069 |
855 |
2.419883 |
| Recruitment Status |
1613 |
903 |
1.786268 |
| None (earliest Version on record) |
1295 |
1295 |
1.000000 |
| Study Design |
1073 |
763 |
1.406291 |
| Outcome Measures |
770 |
491 |
1.568228 |
| Study Description |
726 |
339 |
2.141593 |
| Sponsor/Collaborators |
539 |
375 |
1.437333 |
| Arms |
538 |
374 |
1.438503 |
| Interventions |
538 |
374 |
1.438503 |
| Eligibility |
535 |
339 |
1.578171 |
| Study Identification |
404 |
279 |
1.448029 |
| Oversight |
270 |
236 |
1.144068 |
| References |
233 |
142 |
1.640845 |
| Conditions |
192 |
159 |
1.207547 |
| More Information |
123 |
63 |
1.952381 |
| IPDSharing |
120 |
113 |
1.061947 |
| Results |
96 |
96 |
1.000000 |
| Documents |
49 |
38 |
1.289474 |
| Baseline Characteristics |
44 |
32 |
1.375000 |
| Results Submission Events |
44 |
44 |
1.000000 |
| Reported Adverse Events |
37 |
33 |
1.121212 |
| Participant Flow |
31 |
27 |
1.148148 |
| 2020 Outcome Measures |
1 |
1 |
1.000000 |
| 2020 Study Status |
1 |
1 |
1.000000 |
| Quality Control Review has not concludedReturned: June 19 |
1 |
1 |
1.000000 |
| Quality Control Review has not concludedReturned: May 27 |
1 |
1 |
1.000000 |
Enrollment Metrics by Phase
| Min. |
10.000 |
2.0000 |
2.00000 |
10.00000 |
3.0000 |
10.0000 |
12.0000 |
20.0000 |
| 1st Qu. |
22.750 |
40.0000 |
31.00000 |
31.00000 |
40.0000 |
58.2500 |
82.0000 |
50.0000 |
| Median |
51.500 |
76.0000 |
56.00000 |
66.00000 |
77.0000 |
98.5000 |
192.0000 |
70.5000 |
| Mean |
320.375 |
380.7229 |
65.01176 |
79.66667 |
148.3765 |
104.1875 |
948.9661 |
389.5556 |
| 3rd Qu. |
315.750 |
148.5000 |
84.00000 |
113.00000 |
152.0000 |
122.5000 |
551.5000 |
116.7500 |
| Max. |
1300.000 |
65278.0000 |
320.00000 |
225.00000 |
1700.0000 |
340.0000 |
17500.0000 |
14673.0000 |
Trial Group Type
| Experimental |
1648 |
| Active Comparator |
598 |
| Placebo Comparator |
359 |
| No Intervention |
197 |
| Other |
109 |
| NA |
51 |
| Sham Comparator |
19 |
Intervention Model
| Parallel Assignment |
909 |
| Single Group Assignment |
164 |
| Crossover Assignment |
157 |
| Factorial Assignment |
50 |
| Sequential Assignment |
9 |
| NA |
6 |
Primary Purpose
| Treatment |
680 |
| Prevention |
322 |
| Basic Science |
106 |
| Other |
76 |
| Supportive Care |
39 |
| NA |
35 |
| Health Services Research |
27 |
| Diagnostic |
7 |
| Screening |
3 |
Observational Studies
Studies by Country
| United States |
48 |
| NA |
15 |
| Denmark |
10 |
| Italy |
9 |
| Canada |
6 |
| Netherlands |
6 |
| Switzerland |
5 |
| China |
4 |
| United Kingdom |
4 |
| Germany |
2 |
| Mexico |
2 |
| Norway |
2 |
| Argentina|Brazil|Chile|Colombia|Costa Rica|Ecuador|Peru|Venezuela |
1 |
| Australia |
1 |
| Austria |
1 |
| Belgium |
1 |
| Brazil |
1 |
| Finland |
1 |
| France |
1 |
| Greece |
1 |
| Hong Kong |
1 |
| Israel |
1 |
| Kazakhstan|Russian Federation |
1 |
| Korea, Republic of |
1 |
| Malawi |
1 |
| Malaysia |
1 |
| Morocco|Tunisia |
1 |
| Russian Federation |
1 |
| Saudi Arabia |
1 |
| Spain |
1 |
| Sweden |
1 |
Sites per Study
| 1 |
119 |
| 2 |
5 |
| 3 |
1 |
| 4 |
1 |
| 5 |
1 |
| 6 |
1 |
| 8 |
1 |
| 11 |
1 |
| 27 |
1 |
| 66 |
1 |
Number of Updates
| 1 |
26 |
| 2 |
36 |
| 3 |
20 |
| 4 |
11 |
| 5 |
9 |
| 6 |
4 |
| 7 |
4 |
| 8 |
3 |
| 9 |
1 |
| 10 |
2 |
| 11 |
1 |
| 12 |
2 |
| 13 |
1 |
| 14 |
3 |
| 16 |
1 |
| 29 |
1 |
| 52 |
1 |
| 65 |
1 |
| 76 |
1 |
| 100 |
1 |
| 132 |
1 |
| 133 |
1 |
| 147 |
1 |
Update History Change Type
| Study Status |
1058 |
106 |
9.981132 |
| Study Description |
225 |
33 |
6.818182 |
| Contacts/Locations |
176 |
60 |
2.933333 |
| None (earliest Version on record) |
132 |
132 |
1.000000 |
| Study Design |
123 |
66 |
1.863636 |
| Recruitment Status |
103 |
71 |
1.450704 |
| Eligibility |
77 |
30 |
2.566667 |
| Outcome Measures |
64 |
41 |
1.560976 |
| Sponsor/Collaborators |
49 |
36 |
1.361111 |
| References |
44 |
21 |
2.095238 |
| Study Identification |
34 |
28 |
1.214286 |
| Conditions |
27 |
15 |
1.800000 |
| Oversight |
24 |
19 |
1.263158 |
| Groups |
23 |
19 |
1.210526 |
| Interventions |
23 |
19 |
1.210526 |
| IPDSharing |
3 |
3 |
1.000000 |
| More Information |
2 |
1 |
2.000000 |
| Results |
2 |
2 |
1.000000 |
| Results Submission Events |
2 |
2 |
1.000000 |
| Baseline Characteristics |
1 |
1 |
1.000000 |
| Documents |
1 |
1 |
1.000000 |
| Participant Flow |
1 |
1 |
1.000000 |
| Reported Adverse Events |
1 |
1 |
1.000000 |
Enrollment Metrics
| Min |
1.00 |
| 1st Qu |
49.25 |
| Median |
148.00 |
| Mean |
762327.13 |
| 3rd Qu |
602.25 |
| Max |
99999999.00 |
Observation Model
| Cohort |
66 |
| Other |
18 |
| NA |
13 |
| Case-Control |
12 |
| Case-Only |
8 |
| Case Control |
6 |
| Ecologic or Community |
4 |
| Case-Crossover |
3 |
| Family-Based |
2 |
Time Perspective
| Prospective |
79 |
| Cross-Sectional |
32 |
| Retrospective |
14 |
| Other |
5 |
| NA |
2 |
Registries
Studies by Country
| United States |
4 |
| Colombia |
1 |
Update History Change Type
| Study Status |
19 |
4 |
4.75 |
| Contacts/Locations |
7 |
4 |
1.75 |
| None (earliest Version on record) |
5 |
5 |
1.00 |
| Recruitment Status |
5 |
4 |
1.25 |
| Sponsor/Collaborators |
5 |
2 |
2.50 |
| Eligibility |
2 |
2 |
1.00 |
| Groups |
2 |
1 |
2.00 |
| Interventions |
2 |
1 |
2.00 |
| Study Description |
2 |
2 |
1.00 |
| Outcome Measures |
1 |
1 |
1.00 |
| Oversight |
1 |
1 |
1.00 |
| Study Identification |
1 |
1 |
1.00 |
Enrollment Metrics
| Min |
60 |
| 1st Qu |
80 |
| Median |
100 |
| Mean |
2070 |
| 3rd Qu |
110 |
| Max |
10000 |
Registry Model
| Case-Only |
2 |
| Cohort |
2 |
| Other |
1 |
Time Perspective
| Prospective |
3 |
| Cross-Sectional |
2 |
Follow-up
| 1 Year |
1 |
| 16 Weeks |
1 |
| 3 Months |
1 |
| 6 Months |
1 |
| 7 Days |
1 |